Stay updated on Niraparib + Dostarlimab in Platinum Resistant Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Niraparib + Dostarlimab in Platinum Resistant Ovarian Cancer Clinical Trial page.

Latest updates to the Niraparib + Dostarlimab in Platinum Resistant Ovarian Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe page's revision label shows v3.6.5, replacing v3.6.4. This indicates a small metadata update to the page revision history without changing the study content.SummaryDifference0.0%

- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedA new revision tag, v3.6.4, has been added to replace the previous v3.6.3, signaling a minor site deployment update rather than changes to the study information.SummaryDifference0.0%

- Check52 days agoChange DetectedFooter revision tag updated from v3.6.2 to v3.6.3, reflecting a new page revision.SummaryDifference0.0%

- Check59 days agoChange DetectedVersion bump from v3.6.0 to v3.6.2 indicates a new platform release. It likely includes internal fixes or refinements and does not imply changes to study content or user-facing information.SummaryDifference0.0%

- Check73 days agoChange DetectedEnrollment is now closed with a note that participants are no longer being sought. The page's navigation and headings were updated (e.g., addition of 'How to Read a Study Record', 'Common Questions', 'How to Join a Study', and the formatting change from 'Intervention / Treatment' to 'Intervention/Treatment'), along with a page revision tag 'Revision: v3.6.0'.SummaryDifference0.4%

- Check80 days agoChange DetectedThe page revision was updated from v3.5.4 to v3.5.5, indicating a small update to the page metadata or layout without altering study content.SummaryDifference0.0%

Stay in the know with updates to Niraparib + Dostarlimab in Platinum Resistant Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Niraparib + Dostarlimab in Platinum Resistant Ovarian Cancer Clinical Trial page.